Latest Content

Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC

January 25th 2025, 4:00pm

By Jordyn Sava

Article

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer

January 25th 2025, 3:02pm

By Kristie L. Kahl

Article

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.

Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract

January 24th 2025, 8:39pm

By Megan Hollasch

Article

A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.

Bezuclastinib Plus Sutent May Be Safe and Effective in GIST

January 24th 2025, 6:30pm

By Ryan Scott

Article

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

When Cancer Is Not the Only Thing Going On

January 24th 2025, 6:00pm

By Danielle Ripley-Burgess

Article

My journey as a foster parent paralleled my cancer experience, both demanding resilience, support, and a redefinition of normal.

Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis

January 24th 2025, 5:18pm

By Spencer Feldman

Article

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS

January 24th 2025, 4:15pm

By Ryan Scott

Article

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T

January 24th 2025, 4:00pm

By Alex Biese

Article

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers

January 24th 2025, 2:00pm

By Chris Ryan

Article

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.

Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer

January 23rd 2025, 10:15pm

By Jason M Broderick

Article

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

SHR-1701 Combo Reduces Chemo-Related Myelosuppression in Gastric/GEJ Cancer

January 23rd 2025, 9:35pm

By Tim Cortese

Article

SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Afinitor Plus Somatuline Prolongs Survival in GEP-NETs

January 23rd 2025, 7:00pm

By Tim Cortese

Article

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

Matching Patient Needs with Oncologists’ Strengths in Cancer Care

January 23rd 2025, 6:02pm

By Sue McCarthy

Article

Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are the best doctor for my needs.

The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma

January 23rd 2025, 4:00pm

By Ryan Scott

Article

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Driving Awareness, Action and Empowerment During Cervical Cancer Awareness Month

January 23rd 2025, 2:00pm

By Ryan Scott

Article

Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.